Ensatinib approved for listing

2020/11/23

The listing application for ALK inhibitor Ensatinib Hydrochloride submitted by Betta Pharmaceuticals was approved by the National Medical Products Administration. Ensatinib is a new generation of strong and selective ALK inhibitor independently developed by Betta Pharmaceuticals. The indications declared this time are: used for those who have been treated with crizotinib or Crizotinib can not tolerate ALK-positive locally advanced or metastatic non-small cell lung cancer patients with new treatments.